Zhang, Tian

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Combination strategies to maximize the benefits of cancer immunotherapy

Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 654

Handoffs in the Era of Duty Hours Reform: A Focused Review and Strategy to Address Changes in the Accreditation Council for Graduate Medical Education Common Program Requirements

DeRienzo, C. M., Frush, K., Barfield, M. E., Gopwani, P. R., Griffith, B. C., Jiang, X. “., Mehta, A. I., Papavassiliou, P., Rialon, K. L., Stephany, A. M., et al. (2012) · Academic Medicine

Hospital Admissions and OutcomesInnovations in Medical Education

Cited by 97

Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer

Tian, J., Min, Y., Rodgers, Z., Wan, X., Qiu, H., Mi, Y., Tian, X., Wagner, K. T., Caster, J. M., Qi, Y., et al. (2017) · Nanomedicine: Nanotechnology, Biology and Medicine

Nanoparticle-Based Drug DeliveryAdvanced Drug Delivery Systems

Cited by 25

Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)

Iyer, G., Siefker-Radtke, A., Milowsky, M., Shore, N., Gao, X., Reimers, M. A., Hahn, N., Cosman, R., Matsubara, N., Necchi, A., et al. (2023) · Cancer Research

Fibroblast Growth Factor ResearchLung Cancer Treatments and Mutations

Cited by 12